Download PDF
Geburtshilfe Frauenheilkd 2019; 79(11): 1164-1167
DOI: 10.1055/a-0833-1080
GebFra Magazin
Aktuell diskutiert
Georg Thieme Verlag KG Stuttgart · New York

Schwangerschaft und mütterliche Chemotherapie – Nebenwirkungen für das Kind?

Mara Schneider
,
Julia Winter
,
Krystyna Poplawska
,
Alexandra Anette Russo
,
André Lollert
,
Doris Macchiella
,
Eva Mildenberger
Further Information

Publication History

Publication Date:
11 November 2019 (online)

Also available at
   Permissions and Reprints

Malignome in der Schwangerschaft sind seltene Ereignisse, die Inzidenz ist derzeit jedoch ansteigend. Wissenschaftliche Erkenntnisse und klinische Erfahrungen bei der Therapie schwangerer Frauen mit Malignomen stammen aus retrospektiven Fallserien. Auswirkungen auf das (un-)geborene Kind sind bislang wenig untersucht. Wir stellen ein in utero gegenüber Cytarabin exponiertes Frühgeborenes mit schwerem respiratorischem Krankheitsverlauf vor.
 

  • Literatur

  • 1 Vandenbriele C, Dierick D, Amant F. et al. The treatment of hematologic malignancies in pregnancy. Facts Views Vis Obgyn 2010; 2: 74-87
    PubMedGoogle Scholar
  • 2 Rizack T, Mega A, Legare R. et al. Management of hematological malignancies during pregnancy. Am J Hematol 2009; 84: 830-841
    CrossrefPubMedGoogle Scholar
  • 3 Adam C, Oduncu FS. Hämatologische Neoplasien in der Schwangerschaft. Onkologe 2012; 18: 344-350
    CrossrefPubMedGoogle Scholar
  • 4 Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5: 283-291
    CrossrefPubMedGoogle Scholar
  • 5 Al-Anazi KA. Update on leukemia in pregnancy (November 2015). Online: http://www.intechopen.com/books/leukemias-updates-and-new-insights/update-on-leukemia-in-pregnancy Stand: 10.01.2019
    PubMedGoogle Scholar
  • 6 Chang A, Patel S. Treatment of acute myeloid leukemia during pregnancy. Ann Pharmacother 2015; 49: 48-68
    CrossrefPubMedGoogle Scholar
  • 7 Van Calsteren K, Verbesselt R, Van Bree R. et al. Substantial variation in transplacental transfer of chemotherapeutic agents in a mouse model. Reprod Sci 2011; 18: 57-63
    CrossrefPubMedGoogle Scholar
  • 8 Van Calsteren K. Chemotherapy during pregnancy: pharmakokinetics and impact on foetal neurological developement. Facts Views Vis Obgyn 2010; 2: 278-286
    PubMedGoogle Scholar
  • 9 Hewlett RI, Wilson AF. Adult respiratory distress syndrome following aggressive management of extensive acute lymphoblastic leukemia. Cancer 1977; 39: 2422-2425
    CrossrefPubMedGoogle Scholar
  • 10 Haupt HM, Hutchins GM, Moore GW. Ara-C lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia. Am J Med 1981; 70: 256-261
    CrossrefPubMedGoogle Scholar
  • 11 Borje S, Andersson MD, Brad M. et al. Subacute pulmonary failure complicating therapy with high-dose Ara-C in acute leukemia. Cancer 1985; 56: 2181-2184
    CrossrefPubMedGoogle Scholar
  • 12 Tham RT, Peters WG, de Bruine FT. et al. Pulmonary complications of cytosine-arabinoside therapy: radiographic findings. AJR Am J Roentgenol 1987; 149: 23-27
    CrossrefPubMedGoogle Scholar
  • 13 Jehn U, Göldel N, Rienmüller N. et al. Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia. Med Oncol Tumor Pharmacother 1988; 5: 41-47
    PubMedGoogle Scholar
  • 14 Andersson BS, Luna MA, Yee C. et al. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer 1990; 65: 1079-1084
    CrossrefPubMedGoogle Scholar
  • 15 Chiche D, Bico JL, Bernaudin JF. et al. Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF. Eur Cytokine Netw 1993; 4: 147-151
    PubMedGoogle Scholar
  • 16 Shearer P, Katz J, Bozeman P. et al. Pulmonary insufficiency complicating therapy with high dose cytosine arabinoside in five pediatric patients with relapsed acute myelogenous leukemia. Cancer 1994; 74: 1953-1958
    CrossrefPubMedGoogle Scholar
  • 17 Salvucci M, Zanchini R, Molinari A. et al. Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (FLAN) treatment for acute leukemia. Haematologica 2000; 85: 769-770
    PubMedGoogle Scholar
  • 18 Larouche G, Denault A, Prenovault J. et al. Corticosteroids and serious cytarabine-induced pulmonary edema. Pharmacotherapy 2000; 20: 1396-1399
    CrossrefPubMedGoogle Scholar
  • 19 Briasoulis E, Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist 2001; 6: 153-161
    CrossrefPubMedGoogle Scholar
  • 20 Kopterides P, Lignos M, Mentzelopoulos S. et al. Cytarabine-induced lung injury: case report. Anticancer Drugs 2005; 16: 743-745
    CrossrefPubMedGoogle Scholar
  • 21 Forghieri F, Luppi M, Morselli M. et al. Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients. Haematologica 2007; 92: 85-90
    CrossrefPubMedGoogle Scholar
  • 22 Ulrichs F. Bronchoplumonale Dysplasie und Langzeitfolgen. Pneumologe 2016; 13: 51-57
    CrossrefPubMedGoogle Scholar
  • 23 Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics 2009; 10: 1657-1674
    CrossrefPubMedGoogle Scholar
  • 24 Abraham A, Varatharajan S, Karathedath S. et al. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics 2015; 16: 877-890
    CrossrefPubMedGoogle Scholar
  • 25 Abraham A, Devasia AJ, Varatharajan S. et al. Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia. Ann Hematol 2015; 94: 883-885
    CrossrefPubMedGoogle Scholar